GE HealthCare Technologies Inc. · NASDAQ:GEHC

GE HealthCare Technologies — Q4 2023 Earnings Presentation

34 slides from GE HealthCare Technologies's earnings presentation, Feb 6, 2024

  1. Slide 1: 4Q 2023 Earnings Presentation

    4Q 2023 Earnings Presentation February 6, 2024 © 2024 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,”

  3. Slide 3: Strong Performance in 4Q 2023 & Full Year 2023

    Strong Performance in 4Q 2023 & Full Year 2023 • Strong 4Q and full year financial results • Growing R&D; launched 40+ innovations in 2023 addressing key challenges across care pathways • Robust backlog driven by improved global capital equipment landscape • Disciplined capital allocation strategy:

  4. Slide 4: 4Q 2023 Consolidated Performance Summary

    4Q 2023 Consolidated Performance Summary Revenues Organic orders Adjusted EBIT* and Adjusted EPS* Free cash flow* growth** Adjusted EBIT margin* $5.2B 3% YoY $837M $1.18 $956M 5% Organic growth*(1) Book-to-Bill** 16.1% margin (10)% YoY $(31)M YoY 1.05x (100) bps YoY Flat vs prior year Up 11% vs prio

  5. Slide 5: 2023 Consolidated Performance Summary

    2023 Consolidated Performance Summary Revenues Organic orders Adjusted EBIT* and Adjusted EPS* Free cash flow* growth** Adjusted EBIT margin* $19.6B 3% YoY $3.0B $3.93 $1.7B 8% Organic growth*(1) Book-to-Bill** 15.1% margin (15)% YoY $(113)M YoY 1.03x (50) bps YoY Up 60 bps vs prior year Up 16% vs p

  6. Slide 6: Full Year and 4Q 2023 Revenue Performance

    Full Year and 4Q 2023 Revenue Performance Full Year 2023 4Q 2023 (1) Organic revenue growth* +8% Organic revenue growth* +5%(2) Ultrasound Ultrasound $3.5B, +2%*(1) $944M, (2)%*(2) Imaging Total Revenue Imaging Total Revenue $19.6B PCS $5.2B $10.6B, +7%*(1) $2.8B, 4%*(2) PCS $3.1B, +8%*(1) $827M, +4

  7. Slide 7: Delivered 2023 Adjusted Margin* Expansion

    Delivered 2023 Adjusted Margin* Expansion Adjusted Gross Profit Margin* Up 120 bps YoY Commercial Execution • Solid sales price accretion; enhancing commercial win rates; improving Adjusted gross profit margin* Innovation • Improving volumes and higher margin NPIs • Launched 40+ new innovations Stan

  8. Slide 8: 4Q 2023 Imaging Results

    4Q 2023 Imaging Results 4Q 2023 4Q 2022 YoY Revenues $2,830M $2,709M 4%*(1) Segment EBIT $337M $321M 5% Segment EBIT margin 11.9% 11.8% 10 bps Highlights • Organic revenue growth* driven by improved backlog conversion and price • EBIT margin rate up YoY benefiting from Gross margin improvements • Ac

  9. Slide 9: 4Q 2023 Ultrasound Results

    4Q 2023 Ultrasound Results 4Q 2023 4Q 2022 YoY Revenues $944M $956M (2)%*(1) Segment EBIT $244M $285M (14)% Segment EBIT margin 25.8% 29.8% (400) bps Highlights • Organic revenue growth* declined due to a challenging comparison against the same period last year • EBIT margin decreased YoY primarily

  10. Slide 10: 4Q 2023 Patient Care Solutions Results

    4Q 2023 Patient Care Solutions Results 4Q 2023 4Q 2022 YoY Revenues $827M $786M 4%*(1) Segment EBIT $110M $130M (15)% Segment EBIT margin 13.3% 16.5% (320) bps Highlights • Organic revenue growth* driven by progress on price and operational process improvements • EBIT margin down YoY driven by inves

  11. Slide 11: 4Q 2023 Pharmaceutical Diagnostics Results

    4Q 2023 Pharmaceutical Diagnostics Results 4Q 2023 4Q 2022 YoY Revenues $591M $473M 23%*(1) Segment EBIT $144M $109M 32% Segment EBIT margin 24.4% 23.0% 140 bps Highlights • Strong Organic revenue growth* driven by volume that benefited from a favorable comparison vs. 4Q 2022 and pricing actions • E

  12. Slide 12: Cash Performance

    Cash Performance 4Q 2023 Free Cash Flow* Full Year 2023 Cash Highlights • Delivered $1.7B in Free cash flow* and 95% FCF conversion* • Repaid $1B of debt to date beginning in 4Q 2023(1) $987M $956M • FCF* up YoY excluding standalone interest and incremental postretirement benefit payments • Inventor

  13. Slide 13: 2024 Outlook

    2024 Outlook 2023 2024E Organic Revenue Growth*(1) 8% Approximately 4% Adjusted EBIT Margin* 15.1% 15.6% - 15.9% 50 - 80 bps growth Adjusted ETR* 23.7% 23% - 25% Adjusted EPS* $3.93 $4.20 - $4.35 7% - 11% growth Free Cash Flow* $1.7 billion ~$1.8 billion * Non-GAAP financial measure. See appendix fo

  14. Slide 14: Investing in Digital for Future Growth

    Investing in Digital for Future Growth Imaging Ultrasound Imaging Artificial Intelligence Inside Digital Expert Access with remote Verisound connects GE HealthCare’s Announced planned acquisition of MIM scanning enables remote patient existing ultrasound AI and digital solutions Software(1), a leade

  15. Slide 15: Molecular Imaging

    Molecular Imaging Enabling precision care across multiple Oncology Neurology Cardiology care pathways and disease states Helping providers with existing diagnostic agents today … Cerianna DaTscan Rapiscan Metastatic breast cancer Parkinson’s disease Coronary artery disease Vizamyl Myoview AdreView A

  16. Slide 16: Summary

    Summary • Strong financial and operational performance in our first year as public company • Technological advancements, including AI, position us well to deliver clinical and productivity enhancements along care pathways • 2024 guidance reflects an improved capital equipment landscape; on track to

  17. Slide 17: Q&A

    Q&A © 2024 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  18. Slide 18: Thank You

    Upcoming Events BTIG Snowbird Conference - Virtual February 13, 2024 Citi Unplugged MedTech and Life Sciences Access Day February 29, 2024 Oppenheimer Annual Healthcare MedTech and Services Conference - Virtual March 12, 2024 Barclays Global Healthcare Conference March 14, 2024 Thank You © 2024 GE H

  19. Slide 19: Appendix

    Appendix © 2024 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  20. Slide 20: Total Revenues to Organic Revenue*

    Total Revenues to Organic Revenue* ($ in millions) Three months ended December 31 For the years ended December 31 Unaudited 2023 2022 % change 2023 2022 % change Total revenues $ 5,206 $ 4,938 5% $ 19,552 $ 18,341 7% Less: Acquisitions(1) 1 — 1 — Less: Dispositions(2) — — — — Less: Foreign currency

  21. Slide 21: Segment Revenues to Organic Revenue*

    Segment Revenues to Organic Revenue* ($ in millions) Three months ended December 31 For the years ended December 31 Unaudited 2023 2022 % change 2023 2022 % change Imaging revenues $ 2,830 $ 2,709 4%$ 10,581 $ 9,985 6% Less: Acquisitions(1) 1 — 1 — Less: Dispositions(2) — — — — Less: Foreign currenc

  22. Slide 22: Net Income to Adjusted EBIT* and Standalone Adjusted EBIT* (estimated)

    Net Income to Adjusted EBIT* and Standalone Adjusted EBIT* (estimated) ($ in millions) For the three months ended December 31 For the years ended December 31 Unaudited 2023 2022 % change 2023 2022 % change Net income attributable to GE HealthCare $ 403 $ 554 (27)% $ 1,568 $ 1,916 (18)% Add: Interest

  23. Slide 23: Net Income to Adjusted Net Income* and Standalone Adjusted Net Income*

    Net Income to Adjusted Net Income* and Standalone Adjusted Net Income* (estimated) ($ in millions) For the three months ended December 31 For the years ended December 31 Unaudited 2023 2022 % change 2023 2022 % change Net income attributable to GE HealthCare $ 403 $ 554 (27)% $ 1,568 $ 1,916 (18)% A

  24. Slide 24: Adjusted Tax Expense* and Adjusted ETR* Reconciliation

    Adjusted Tax Expense* and Adjusted ETR* Reconciliation ($ in millions) For the years ended December 31 Unaudited 2023 2022 % change Benefit (provision) for income taxes $ (743) $ (563) 32% Add: Tax effect of reconciling items 92 (67) Add: Certain tax adjustments(1) 80 — Adjusted tax expense* $ (571)

  25. Slide 25: Diluted EPS to Adjusted EPS* and Standalone Adjusted EPS*

    Diluted EPS to Adjusted EPS* and Standalone Adjusted EPS* (estimated) (In dollars, except shares outstanding presented in millions) For the three months ended December 31 For the years ended December 31 Unaudited 2023 2022 $ change 2023 2022 $ change Diluted earnings per share – continuing operation

  26. Slide 26: Cash from Operating Activities to Free Cash Flow*

    Cash from Operating Activities to Free Cash Flow* ($ in millions) For the three months ended December 31 For the years ended December 31 Unaudited 2023 2022 % change 2023 2022 % change Cash from (used for) operating activities – continuing operations $ 1,050 $ 1,063 (1)% $ 2,101 $ 2,134 (2)% Cash fl

  27. Slide 27: Non-GAAP P&L Reconciliations - 4Q 2023

    Non-GAAP P&L Reconciliations - 4Q 2023 ($ in millions) Acquisition Amortization Non- Income (loss) and (Gain) loss on of Investment Operating Spin-Off and Tax Effect of from GAAP Restructuring disposition- separation business and acquisition- revaluation benefit Certain Tax Non-GAAP Reconciling disc

  28. Slide 28: Non-GAAP P&L Reconciliations - FY 2023

    Non-GAAP P&L Reconciliations - FY 2023 ($ in millions) Acquisition Amortization Investment Non- Income and (Gain) loss on of Spin-Off and acquisition- revaluation Operating Tax Effect of (loss) from GAAP Restructuring disposition- separation business and Certain Tax discontinued Non-GAAP related ben

  29. Slide 29: Non-GAAP P&L Reconciliations - FY 2022

    Non-GAAP P&L Reconciliations - FY 2022 ($ in millions) Acquisition Amortization Non- Income (loss) and (Gain) loss on of Spin-Off and Investment Operating Tax Effect of from GAAP Restructuring disposition- separation business and acquisition- revaluation Certain Tax benefit Reconciling Adjustments(6

  30. Slide 30: Acronyms

    Acronyms AI Artificial Intelligence bps basis points CAF Cancer Associated Fibroblast CT Computed Tomography FCF Free Cash Flow G&A General & Administrative MR Magnetic Resonance NPIs New Product Introductions PET Positron Emission Tomography PET/CT Positron Emission Tomography / Computed Tomography

  31. Slide 31: Definitions

    Definitions Book-to-Bill Total orders divided by total revenues within a given financial period (e.g., quarter or FY) Free cash flow conversion* Free cash flow* / Adjusted net income* Rate of change period-over-period of contractual commitments with customers to provide specified goods or services f

  32. Slide 32: Non-GAAP Financial Measures

    Non-GAAP Financial Measures The non-GAAP financial measures presented in this presentation are supplemental measures of GE HealthCare’s performance and its We believe Adjusted gross profit, Adjusted gross profit margin, Adjusted EBIT, Adjusted EBIT margin, Standalone Adjusted EBIT, and liquidity tha

  33. Slide 33: Non-GAAP Financial Measures in Outlook

    Non-GAAP Financial Measures in Outlook GE HealthCare calculates forward-looking non-GAAP financial measures, including Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and Free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP fin

  34. Slide 34: Slide 34

GE HealthCare — Q4 2023 Earnings Presentation on 6ix